Introducing HPV vaccine in developing countries--key challenges and issues.
Agosti
Jan M
JM
Global Health Program, Bill and Melinda Gates Foundation, Seattle, USA.
Goldie
Sue J
SJ
D000293:Adolescent; D016497:Adolescent Health Services; D052685:Alphapapillomavirus; D003362:Cost-Benefit Analysis; D003906:Developing Countries; D016527:Drug Costs; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18